

POSITION PAPER

Adult penicillin allergy programmes in Australian hospitals: a practical guide from the National Antibiotic Allergy Network

Rory Hannah,¹ Elise Mitri^{2,3}, Constance H. Katelaris,⁴ Jennifer O'Hern,⁵ Minyon Avent,^{6,7} Glenn Valoppi,⁸ Matthew Rawlins⁹, Catherine Frith,^{10,11} Brendan McMullan,^{12,13} David Kong,^{14,15} Kyra Chua,^{2,3} Amy Legg,^{16,17} Rod James,^{14,18,19} Sonja Janson,²⁰ Carolyn Hawkins,^{21,22} Katrina Randall,^{21,22} Courtney Ierano,^{14,19} Karin Thursky^{14,19,23,24} and Jason A. Trubiano^{2,3}

¹Department of Infectious Diseases, Clinical Immunology and Allergy, Division of Medicine, Lyell McEwin Hospital, Adelaide, South Australia, ²Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Austin Health, ³Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, ⁴Slade Pharmacy, Epworth Healthcare, ¹⁴Department of Infectious Diseases, National Centre for Antimicrobial Stewardship, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, ¹⁵Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, ¹⁸Microbiological Diagnostic Unit – Public Health Laboratory, Peter Doherty Institute for Infection and Immunology, Department of Microbiology and Immunology, University of Melbourne, ¹⁹Royal Melbourne Hospital Guidance Group, Melbourne Health, and ²³National Centre for Infections in Cancer, and ²⁴Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, ⁴Immunology/Allergy Unit, Department of Medicine, Campbelltown Hospital and Western Sydney University, Departments of ¹⁰Immunology, and ¹²Infectious Diseases, Sydney Children's Hospital, and School of ¹¹Clinical Medicine, and ¹³Clinical Medicine, Discipline of Paediatrics, University of New South Wales, Sydney, New South Wales, ⁵Department of Infectious Diseases, Launceston General Hospital, Launceston, Tasmania, ⁶Queensland Statewide Antimicrobial Stewardship Program, Queensland Health, ⁷Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), University of Queensland, and ¹⁷Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Queensland, ⁹Department of Pharmacy, Fiona Stanley Hospital, Perth, Western Australia, ¹⁶Menzies School of Health Research, Charles Darwin University, and ²⁰Department of Infectious Diseases, Royal Darwin Hospital and Northern Territory Medical Program, Darwin, Northern Territory, and ²¹Department of Immunology, Canberra Hospital, and ²²School of Medicine and Psychology, Australian National University, Canberra, Australian Capital Territory, Australia

Key words

delabelling, oral challenge, antimicrobial allergy, beta-lactam allergy, penicillin allergy.

Correspondence

Jason A. Trubiano, National Antibiotic Allergy Network, Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Austin Health, Heidelberg, Vic. 3084, Australia.
 Email: jason.trubiano@austin.org.au

Received 20 August 2024; accepted 22 September 2024.

Abstract

Penicillin allergy is a significant burden on patient, prescribing and hospital outcomes. There has been increasing interest in the incorporation of penicillin allergy testing (i.e. delabelling) into antimicrobial stewardship (AMS) programmes to reduce the burden of penicillin allergy labels and improve prescribing. In particular, there has been a focus on point-of-care penicillin allergy assessment and direct oral challenge for low-risk phenotypes. The National Antibiotic Allergy Network has provided a guide to assist AMS clinicians with the incorporation of penicillin allergy programmes, in particular direct oral challenge, into Australian hospitals.

Introduction

Patient-reported penicillin allergies, so-called penicillin allergy labels (PALs), are a high burden in Australian healthcare, with more than 9% of all inpatients reporting such a label.¹ In the Australian and global setting, these have been associated with inappropriate

prescribing, broad-spectrum antibiotic utilisation, poor patient outcomes and antimicrobial resistance.^{1–5} This is despite the vast majority of PALs being low-risk phenotypes (e.g. childhood rash), typically amenable to direct oral challenge (DOC),⁶ with extensive local and international literature supporting the safety of this approach.^{7,8}

Penicillin allergy has been seen as a target for antimicrobial stewardship (AMS) programmes,⁹ supported by national and international AMS policy and guidelines.^{10–12} In fact, the Australian Clinical Care Standards for AMS

Funding: None.

Conflict of interest: None.

include a Quality Statement on Adverse Reactions to Antimicrobials for the hospital setting.¹³ The World Health Organization (WHO) AMS interventions practical guide highlights that the rationale for implementation of penicillin allergy delabelling in hospitals is to improve first-line antibiotic use, reduce antibiotic adverse drug reactions (ADRs), reduce inpatient length of stay, improve antibiotic allergy assessment and save healthcare costs.¹² In prospective cohort studies, inpatient penicillin allergy delabelling programmes have been demonstrated to lead to increased utilisation of narrow-spectrum penicillins, reduced restricted antibiotic prescribing, increased antibiotic appropriateness and cost savings.^{6,14,15}

This guideline therefore seeks to provide guidance for clinicians, particularly those involved in AMS programmes, who seek to deploy penicillin allergy assessment and delabelling in the inpatient hospital setting.

Objective

The objectives of the guide are to provide a practical approach to inpatient penicillin allergy assessment and delabelling programmes and to promote the safe and effective use of penicillins and beta-lactams in patients with a PAL. The guide utilises the available evidence and the experience of the multidisciplinary steering committee from the National Antibiotic Allergy Network (NAAN).

Target audience

The target audience includes primarily hospital AMS providers who are planning to implement one or more penicillin allergy interventions in the hospital setting.

Methods

The NAAN is a group of multidisciplinary clinicians seeking to support the implementation of antibiotic allergy programmes into Australian healthcare. The steering committee has representation from all states and jurisdictions, the AMS Jurisdictional Network, and specialist disciplines, including allergy and immunology, AMS, infectious diseases and pharmacy. The manuscript was developed from a literature search and narrative review using key word search terms: ('delabelling' OR 'antibiotic allergy' OR 'penicillin allergy') AND ('inpatient' OR 'hospital' OR 'antimicrobial stewardship'), identifying studies performed between 2000 and 2024. Current peak society guidelines and local health authority publications were also identified and reviewed, where appropriate. A writing committee (RH, EM, CHK, JAT) was established to provide a draft manuscript for the wider NAAN steering committee to

review. Recommendations were summarised and presented, and line-by-line review was undertaken by the NAAN steering committee with 15 members present, during which consensus recommendations were achieved. Following feedback from the NAAN steering committee, a revised manuscript was provided to the peak AMS bodies for review, comment and endorsement, including the Healthcare Infection Control Special Interest Group from the Australasian Society of Infectious Diseases, National Centre for Antimicrobial Stewardship, Advanced Pharmacy Australia (formerly Society of Hospital Pharmacists of Australia) and the Therapeutic Guidelines.

Key definitions required for understanding penicillin allergy programmes

The key definitions required for the implementation of penicillin allergy programmes and to avoid confusion or ambiguity among stakeholders is provided in Table 1.^{4,9,16–18}

Barriers and facilitators to implementation of penicillin allergy programmes

There are potential barriers and facilitators to the implementation of penicillin allergy programmes in the inpatient setting. Some of the commonly encountered and modifiable barriers and facilitators identified in the literature are described in Table 2 with proposed solutions.

Practice guide

It is important for clinicians commencing inpatient PAL delabelling programmes to

- Understand their local barriers and enablers.
- Leverage identified themes from previous international and local implementation experiences.
- Ensure the existence of an endorsed clinical delabelling protocol, with simplified procedures and practices that focus on low-risk and stable patients.

Models of penicillin allergy care in the hospital setting

A variety of inpatient and ambulatory models of penicillin allergy assessment and delabelling have been reported in the literature, with the majority (>50%) being multidisciplinary in nature,²⁵ and a predominance of allergist, pharmacist and infectious diseases performing the PAL assessment.²⁵ A recent meta-analysis and systematic review by Powell *et al.* demonstrated that delabelling by non-allergists is efficacious and safe.²⁶ These data support

Table 1 Definitions of terms used in the delivery of penicillin allergy programmes

Term	Definition
Penicillin allergy label (PAL)	Patient-reported penicillin allergy, irrespective of immunological or non-immunological mechanism.
Antibiotic allergy label (AAL)	Patient-reported antibiotic allergy, irrespective of immunological or non-immunological mechanism.
Delabelling (delabeling)	Removal of a PAL or AAL following medical reconciliation and/or allergy testing (such as a skin test or direct oral challenge)
Direct delabelling	Removal of a PAL or AAL following medical reconciliation alone. Frequent examples include (i) prior proven tolerance to implicated penicillin (since the time of reported reaction); (ii) a PAL or AAL based upon family history alone; and (iii) where the reaction associated was consistent only with a benign non-immunological reaction (e.g. isolated gastrointestinal upset).
Direct oral challenge (DOC)	Performing an oral challenge or provocation, single dose or multistep, without prior skin testing.
Desensitisation	Temporary induction of tolerance to a sensitised drug by administering slow increments of the drug, starting from a very small amount to a full therapeutic dose.
Low-risk penicillin allergy	PAL that represents a phenotype unlikely to be reproducible on oral challenge with or without prior skin testing and not associated with severe or life-threatening symptoms or signs.
High-risk penicillin allergy	PAL that represents a phenotype either likely to be reproducible on oral challenge with or without prior skin testing or phenotype where the potential morbidity or mortality from re-exposure is significant (i.e. anaphylaxis, severe cutaneous adverse drug reactions).
Anaphylaxis	Anaphylaxis is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. Severe anaphylaxis is characterised by potentially life-threatening compromise in breathing and/or circulation and may occur without typical skin features or circulatory shock being present.
Severe cutaneous adverse reactions	A group of severe presumed T-cell-mediated delayed hypersensitivities – Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms and acute generalised exanthematous pustulosis.

Table 2 Barriers to implementation of penicillin allergy programmes

Barriers to implementation	Proposed solutions/enablers
Hospital framework and support	- Utilise an evidence-based approach focussed on stable ward patients, with hospital executive support to improve healthcare worker confidence.^{7,19} - Allergist support should be considered for determining approaches to complex penicillin allergy phenotypes.²⁰
Stakeholder time pressures ^{20,21}	Busy clinicians are more engaged when the PAL impacts current antibiotic needs. Proposed solutions by end-users include the following²⁰: - Utilise an acute antibiotic need as a driver for penicillin DOC. - Reduce observation times after DOC. - Ensure there is a named leader or champion for delabelling.
Patient acceptance and prevention of relabelling	Relabelling is noted to be higher in patients who have had direct delabelling compared to DOC²² and in those who have not been provided written confirmation of their delabelling.²³ Patient acceptance of delabelling and reduced rates of relabelling are optimised when - The benefits of delabelling are clearly explained.^{22,24} - DOC is utilised when feasible. - Written communication is provided after testing. Consider using NAAN-developed and consumer-approved consumer information sheets (Appendix S1).
Facilitators to implementation	Drivers
National standards for accurate and complete documentation of adverse reactions to antimicrobials in the medical record. ¹³	The AMS Clinical Care Standards advocate for quality documentation, including the active ingredient, date, nature and severity, of an adverse reaction to any antimicrobial in the healthcare record. These standards support Hospital Accreditation Frameworks to promote safe and appropriate antimicrobial prescribing. ¹³
Utilisation of penicillin allergy delabelling as a method for improved antibiotic appropriateness	National and international AMS guidelines and guides, ^{10,12} support the use of penicillin allergy delabelling as an effective tool for improved antibiotic appropriateness and narrow-spectrum penicillin utilisation.

a multidisciplinary model,¹⁹ noting the importance of utilising an engaged workforce with expertise and motivation, irrespective of discipline.²⁰

A recent state-wide initiative led by Safer Care Victoria implementing inpatient penicillin allergy programmes across 12 hospitals demonstrated the following factors as

drivers for successful programme implementation: AMS involvement (75%), utilisation of a validated antibiotic allergy assessment tool²⁷ or clinical decision rule (PEN-FAST) (83%)²⁸ and DOC completion via a hospital-approved protocol (97%).^{29,30} Engaging consumers in the process of DOC and delabelling is an increasing focus. Loprete *et al.* in a New South Wales experience demonstrated that written communication to patients improved short-term patient perception of beta-lactam allergy status.²³ Examples of NAAN endorsed written communication for consumers and clinicians are provided in Appendix S1.

Considering the focus on hospital AMS outcomes, only those models appropriate to the inpatient care setting are discussed in this practice guide. These models have been separated into *whole-of-hospital* approaches and *selected* delabelling models. Proposed future models of inpatient penicillin allergy delabelling may include a decentralised service, supported by education, whereby activity is less reliant on AMS programmes.

Whole-of-hospital delabelling

A penicillin allergy delabelling programme supported by the Victorian Department of Health was piloted at two Victorian centres in 2019–2020.⁶ As part of this programme, daily assessment and review of all inpatients reporting a penicillin allergy in the Electronic Medical Record (EMR) system was undertaken (Monday–Friday). A delabelling strategy was offered to appropriately assessed low-risk patients who met predefined inclusion and exclusion criteria.⁶ This programme was successful in delabelling 29% of patients assessed, with 97% negative on DOC.⁶ A similar programme of prospective assessment was performed in New Zealand, with a higher conversion of assessment to delabelling (71%) and equivalent safety profile (91% negative on DOC).³¹ Similar findings were noted in a study undertaken by internal medicine clinicians in Norway, with 63% of patients who were assessed as low-risk proceeding to DOC.³² Such programmes are advantageous in reach and are more likely to meet the recommended antibiotic allergy documentation criteria in the healthcare record, according to the AMS Clinical Care Standard.¹³ However, they remain resource intensive and are difficult to implement in hospitals without an EMR, and the conversion from assessment to delabelling is often incomplete.

Selective delabelling

In contrast to whole-of-hospital programmes, selective delabelling strategies can be deployed, including opportunistic (i.e. no acute therapeutic penicillin requirement) and targeted (i.e. acute therapeutic penicillin requirement) programmes. AMS-led penicillin allergy rounds

have been described in the local Australian literature to perform both aforementioned described methods – using a post-prescription format directed by an EMR custom list of PAL patients with/or without current antibiotic utilisation and criteria-led DOC – resulting in improved prescribing and delabelling opportunities.^{33,34} The rounds in these models typically were weekly and multidisciplinary (i.e. pharmacist and clinician), offered penicillin allergy assessment and direct delabelling and DOC (where applicable) and focussed on antimicrobial prescribing.^{15,35}

(i) **Opportunistic delabelling:** Providing delabelling to an inpatient not acutely requiring a penicillin has greatest support in frequent users of antibiotics (e.g. immunocompromised) and perioperative settings.^{36,37} However, outpatient models are more successfully and frequently reported in patients not actively requiring antibiotics.^{38–41} In an Australian multicentre cohort study by Trubiano and colleagues, patients who were opportunistically delabelled during an inpatient admission and likely to receive a penicillin in the 12 months after DOC were those who were admitted with an infective episode or on a surgical admission or who were immunocompromised.³⁶

(ii) **Targeted delabelling:** The literature, both locally and internationally, has greater volume of penicillin allergy assessment being performed in targeted settings, for example, infective episode or current antibiotic utilisation.²⁵ Internationally, Ramsey and colleagues utilised an AMS pharmacist to screen an EMR-generated report of patients with a PAL who were receiving antibiotics. Low-risk patients who provided consent were interviewed by an allergist using telehealth, were assessed utilising a previously developed assessment tool (penicillin allergy history algorithm (PAHA); Table S1), and consented to DOC.³⁵ In Australia, Li *et al.* deployed a programme where patients with a PAL who required penicillin antibiotic therapy could be referred by AMS and treating clinicians, using predefined low-risk criteria, to an inpatient allergy service for assessment and DOC if appropriate.¹⁵ Trubiano and colleagues demonstrated potentially the highest reward targets for inpatient penicillin allergy programmes (i.e. low-risk phenotypes most likely to convert from assessment to DOC) as patients who were admitted with an infective episode or had a surgical admission.³⁶ Further, Australian programmes have also demonstrated the sustainability of inpatient DOC programmes, with a focus on targeted delabelling.⁴²

Practice guide

- For hospitals with established AMS services, the incorporation of antibiotic allergy assessment is easiest to

achieve via opportunistic and targeted delabelling models.

- The incorporation of AMS/allergy rounds in a post-prescription review format is a validated approach, as is utilising AMS clinicians to 'flag' patients to established inpatient allergy services.
- Most published models utilise an EMR custom list of PAL patients receiving antibiotic therapy, screened by an AMS pharmacist.
- While whole-of-hospital approaches are likely reserved for well-resourced programmes, they can aid the attainment of improved hospital assessment to meet the National AMS Clinical Care Standard¹³ but are unlikely to translate to DOC for all low-risk patients. Hence, such programmes may be more effective in high-antibiotic usage wards (e.g. surgical, haematological, transplant).
- A focus on written communication to patients is likely to improve delabelling and DOC outcome uptake.

How to undertake and implement patient-level penicillin allergy assessment

There are a variety of validated assessment tools that can be utilised at point of care for the assessment of a PAL. Validated assessment tools are designed to ascertain allergy risk, determine the suitability of penicillin and other beta-lactams, enable consideration of a delabelling strategy and aid clinician prescribing of alternative beta-lactams (see Therapeutic Guidelines for recommendations of alternative antibiotics where beta-lactams cannot be used⁴³).

The available assessment tools have recently been reviewed by Wrenn and Trubiano¹⁹ and are demonstrated in Table S1. These tools have been validated in the inpatient, rural/remote, paediatric, critical care and immunocompromised host setting. It is recommended that programmes have a method for patient assessment to aid complete documentation of the four antibiotic allergy criteria in the patient medical record, as required by Australian Clinical Care Standards¹³: (i) active ingredient, (ii) nature of reaction, (iii) date and (iv) severity. The 'severity' remains subjective, and at present there is no nationally endorsed grading for low-, moderate- and high-severity reactions.

Assessment of PAL alone provides an opportunity for intervention – in patients who have undergone assessment and demonstrated tolerance of the implicated penicillin after the index reaction, direct delabelling has been commonly performed.⁴⁴ While direct delabelling has also been successfully reported in inpatient PAL delabelling programmes, in those with a reported intolerance of type A ADR (i.e. pharmacologically predictable non-immune

mediated side effect),^{6,31,33} there is infrequent reporting of this practice and inconsistency with which intolerances can be directly delabelled.⁴⁴ Depending on clinician and patient acceptance of direct delabelling for type A ADR to penicillin, DOC, without the requirement for intensive monitoring, may be deployed as an alternative.

The assessment of low-risk PALs can be either via a clinical decision rule or via predefined criteria.²⁵ Clinical decision rules aim to define low risk typically by a scoring system or algorithm (Table S1). The only Australian-derived and randomised control trial-validated penicillin allergy clinical decision rule is PEN-FAST²⁸ (Fig. 1). PEN-FAST is a three-point clinical decision rule that has a 96% negative predictive value of asserting a negative DOC²⁸ and was demonstrated in a recent international randomised control trial (PALACE Study) to be able to direct low-risk patients safely to DOC in lieu of skin testing followed by oral challenge.⁴⁵ PEN-FAST has also been adapted for varied populations and settings,^{46,47} including immunocompromised hosts and critical care,^{42,48} but is not appropriate for use in paediatric patients after failed external validation.⁴⁹ A PEN-FAST score of <3 can be used to ascertain a low-risk phenotype, especially for non-allergists. There are a range of criteria-led low-risk definitions, which are primarily expert opinion derived.²⁵ Local Australian guidelines from the Australasian Society of Clinical Immunology and Allergy have provided a criteria-led framework to describe low-risk phenotypes: benign rash without mucosal involvement or




Figure 1 PEN-FAST clinical decision rule.²⁸

systemic symptoms >5 years ago.⁵⁰ This is supported by the recent US Practice Parameters: benign cutaneous reaction more than 5 years ago.⁵¹ The criteria demonstrated in the literature, while heterogenous in nature, are consistent that a benign or childhood rash >1–5 years ago is considered low risk (Table S1).

Practice guide

We recommend that hospitals develop an assessment strategy that is able to ascertain the four key criteria required for antibiotic allergy documentation as defined by the AMS Clinical Care Standard – that is:

- Active ingredient (implicated drug), as specific as possible
- Nature of the reaction
- Date of the reaction, or as specific as possible
 - For example, <1 year ago, <5 years ago, >5 years ago
- Severity of the reaction

Following local review, an assessment tool should be chosen with consideration of adaptation for the care setting. A PEN-FAST score of <3 (clinical decision rule) or criteria of childhood exanthema or benign rash >1–5 years ago (criteria-led) are low-risk phenotypes that are prime targets for DOC.

Approaches to inpatient DOC in low-risk patients

There is increasing evidence for the safety and efficacy of DOC (single or multistep) with the implicated penicillin or amoxicillin in the setting of low-risk PAL to effect inpatient delabelling^{5,7} (Table S2). Mitri *et al.* performed a recent scoping review of direct oral penicillin challenge in the community, outpatient and inpatient settings, identifying 6394 DOC, noting heterogeneity of low-risk criteria to direct challenge. Nonetheless, universally anaphylaxis and severe cutaneous adverse reactions (SCAR) (high-risk features) were excluded.²⁵ The negative challenge rate in a recent review of inpatient DOC was 91%–100% in the reported literature and in the Australian setting a rate of 96.4%–98.5% with no serious adverse events (SAEs).²⁵

There is considerable heterogeneity in the practice of DOC, regarding dose (250–1000 mg), steps (one step, two steps, more than two steps), agent (phenoxymethylpenicillin, amoxicillin), observation period (30 min to 2 h) and stakeholder delivery. From a recent review 71% of DOC publications utilised amoxicillin as the agent, and 29% used the implicated penicillin.

On review of the literature at present, there is no clear difference in safety outcomes between single-versus multistep DOC and choice of agent, with 57% of the literature deploying single-dose DOC, 28% utilising a multistep design and the remainder ill defined.²⁵ The largest study of inpatient DOC ($n = 478$) utilised a single-dose approach without SAE.⁴² The route of challenge in the literature has primarily been oral; however, nasogastric has been used in a critical care setting and clinical practice.⁴⁸ The consideration of prolonged oral challenges (i.e. >1 dose) remains controversial, with a recent meta-analysis providing no clear benefit, although there remains an absence of controlled studies.⁵²

The observation period for DOC protocols varies from 30 min to 2 h,²⁵ with 66% of studies observing patients for 60 min after DOC, without a clear definition of what constitutes ‘observation’. In a review of the inpatient DOC data by Rose *et al.*, there was no stipulation of time to positive challenge.⁷ There was no report of SAE in the Australian experience.⁷ In most clinical experiences nursing staff have provided the direct observation with medical teams’ involvement primarily in the setting of DOC consent and finalisation of challenge result.^{6,15,25} There is limited documentation in protocols for the requirement of cannulation or pre-emptive prescribing of medications such as adrenaline or anti-histamines.

With regard to the stakeholder involved in the delivery of inpatient DOC, there are varied approaches as outlined below:

- *Primary assessment:* There remains heterogeneity in the discipline performing the primary assessment. Sixty per cent of DOC publications report a multidisciplinary team in the delivery of the programmes.
- *Prescribing:* 70% of studies utilised an allergist or non-allergist specialist (e.g. infectious diseases physician) for the prescription of the DOC.²⁵ While there is emerging evidence for pharmacist-led prescribing, physician-led DOC is presently supported by the literature.
- *Follow-up procedures after DOC:* There remains an absence of literature describing study follow-up procedures after DOC, with only 49% reporting an element of ‘follow-up’ which is heterogenous in nature.²⁵ In practice, therapeutic doses of a penicillin can follow immediately after a DOC has been completed.

Practice guide

The following are suggested approaches to performing a penicillin DOC:

- **Consent:** Obtain informed written consent prior to DOC. If written consent is not possible, document clear verbal consent in the patient medical record.
- **Drug administration:** Single-dose challenge with 250–500 mg oral or nasogastric amoxicillin.
 - Where the implicated penicillin is known, this may be used.
 - A single-dose oral challenge, without extended challenge, is the preferred method. A multistep challenge may be performed where this would aid consumer or stakeholder acceptance of the process.
 - Noting the dose is a ‘challenge’ in the prescription is suggested to provide clarity to nursing, pharmacy and medical teams.
 - Precharting of emergency medications or cannulation prior to DOC is not required.
- DOC should be performed within hospital ‘business hours’, unless being undertaken in higher acuity settings.
- **Observations:** We recommend performing a baseline set of observations in the inpatient setting to exclude concurrent medical instability prior to commencing DOC. We recommend a minimum observation period of 60 min, with consideration of visual or objective observations being performed at 30-min intervals. Primary nursing-led observations, with medical staff available to review in the event of an adverse event and to finalise the result of the challenge, is preferred.
- **Follow-up:** Patient telephone or in-person follow-up after DOC is preferred. If not feasible, it is recommended to provide care team contact details for patients to use in the event of a reported adverse event after DOC.
- **Consumer communication:** The outcome of the DOC should be communicated to the patient with a clear verbal explanation accompanied by a simple patient information letter. Correspondence with the GP and other relevant specialists should be completed.
- **EMR documentation:** The outcomes of penicillin oral challenge should be updated in the hospital record and uploaded to the patient’s My Health Record, including delabelling of the penicillin allergy in the event of a negative challenge. See Appendix S1 *NAAN Inpatient DOC Checklist* for further details.
- Therapeutic penicillins can be utilised immediately after a negative DOC.

How to undertake inpatient skin testing in moderate- to high-risk patients

The body of evidence for skin prick (SPT) and intradermal testing (IDT) lies in the outpatient setting; however, over the last decade increasing reports of inpatient AMS or infectious diseases-led skin testing

have been demonstrated, in particular in the United States.^{19,53,54} A standard panel of skin testing reagents must be appropriate for the Australian setting and within Therapeutic Goods Administration approval. Therefore, the Diater benzylpenicilloyl-polylysine (PPL) and minor determinant mixture (MDM), which were primarily validated in Europe, are recommended,⁵⁵ in combination with benzylpenicillin 10 000 units and ampicillin (or amoxicillin) at 20–25 mg/mL for SPT and IDT.⁵⁶ The cost of the Diater preparation has been prohibitive in the Australian context, and the role of MDM remains controversial.⁵⁷ This should only be performed with a skilled workforce with experience in the delivery and interpretation of SPT and, in particular, IDT. Skin testing alone does not remove a PAL and, in the setting of a negative IDT, must be followed by oral or intravenous provocation as per site local protocol. The acute need for SPT/IDT in high-risk testing is also further mitigated in the 21st century by (i) desensitisation⁵⁸ and (ii) application of cross-reactivity principles,^{59,60} which enable the use of any non-cross-reactive cephalosporin in a reported PAL (excluding in SCAR phenotypes).⁵¹

Practice guide

Considering the cost of reagents, human resources and training required to deliver inpatient skin testing, this practice should be avoided as a primary objective, and the focus should remain on DOC for low-risk phenotypes and the application of cross-reactivity principles to enable cephalosporin utilisation in patients with a PAL.

What is a positive challenge?

Patient-reported symptoms following a drug allergy challenge are frequently reported; however, few are immune-mediated reactions that should result in the persistence of the PAL. While grading systems for ascertaining positive challenges have been identified primarily for food reactions, drug allergy is less well defined. Khan *et al.* recently proposed a grading system for immediate reactions (<6 h after dose) of no reaction and grade 0–4.⁶¹ Grades 1–4 are considered a positive challenge, with grades 3 and 4 defined as severe and life-threatening respectively. In particular, isolated gastrointestinal reactions, tingling, subjective lip swelling, dyspnoea, palpitations, light-headedness, hypertension, cough, chest tightness, throat sensation without objective findings, subjective itch without rash and headache are labelled a grade 0 reaction and not considered an allergy. This grading system does not cover delayed

hypersensitivities, and of note some delayed hypersensitivities may occur within 6 h of dose, especially on rechallenge.⁶²

Practice guide

Patients reporting subjective signs or symptoms should be encouraged that these responses are not a true allergy and do not preclude the future use of the medication. This may require an open discussion, reinforcement and encouragement by the medical team. A grading system can be utilised by clinicians to help provide clarity of true positive challenges.

Summary of practice guide statements

This paper provides a practice guide to the delivery and implementation of penicillin allergy programmes in the inpatient setting, with a focus on AMS practices and addressing the Australian healthcare context. A summary of an approach to inpatient PAL assessment and delabelling is provided in Figure 2. A practical procedural guide for inpatient DOC is provided in Appendix S1. Specific key practice guide statements are provided as follows:

- Addressing local barriers and enablers to PAL assessment and delabelling at the health service is central to the delivery of a penicillin allergy programme.
- A variety of assessment tools and clinical decision rules are available for use and should be piloted and adapted to your workflow to increase healthcare worker engagement and participation.
- DOC can be performed safely on an inpatient ward with a preference for patients with (i) acute antibiotic need, (ii) clinical stability and (iii) low-risk phenotypes.
- The definition of low-risk phenotypes amenable to inpatient DOC are either clinical decision rule-led (PEN-FAST <3) or criterion-led (childhood rash or benign cutaneous exanthema >1–5 years ago).
- DOC can be performed in acute or subacute care with preference given to (i) single-dose challenge, (ii) amoxicillin 250–500 mg, (iii) 60 min minimum observation period and (iv) no pre-prescription of emergency medications.
- Informed written consent is recommended prior to DOC. Where this is not possible, clear documentation of verbal consent should be in the patient medical record.
- Written communication following a successful or unsuccessful challenge should be provided to patients




Figure 2 Suggested approach to penicillin allergy in inpatient setting. †Selective delabelling – the implementation of delabelling strategies in the inpatient setting that are targeted (i.e. penicillin allergy assessment and/or direct oral challenge (DOC) when acute antibiotic need) or opportunistic (i.e. penicillin allergy assessment and/or DOC when there is no acute antibiotic need but in host likely to require future penicillin utilisation). ‡Direct oral challenge – amoxicillin; 250–500 mg single-dose challenge; routine inpatient wards; observation period minimum 60 min. §Direct delabelling – removal of allergy label following assessment and/or medical reconciliation. ¶Following DOC, irrespective of positive or negative challenge provide written communication to patient and clinicians (inpatient and community), Examples of consumer information and post-DOC documentation can be found in Appendix S1.

and clinicians to help aid delabelling documentation and sustainability. Clinicians should also provide a clear verbal explanation of the outcome and meaning of the DOC results, with opportunity for questions.

- Positive challenges can be defined by a recently published grading system to help avoid over-labelling of patients reporting subjective symptoms following a DOC.
- The model of penicillin allergy programme must be adapted to the requirements and resources available at

the health service. Evidence is supportive of a multi-disciplinary model which is AMS-led in the inpatient space utilising custom or EMR-generated lists of patient capture.

ACKNOWLEDGMENT

We thank the Medicines Team at Safer Care Victoria for review of the guide and the Western Australian Committee for Antimicrobials for endorsement.

References

- Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavin MA, Thursky KA *et al.* Antimicrobial allergy 'labels' drive inappropriate antimicrobial prescribing: lessons for stewardship. *J Antimicrob Chemother* 2016; **71**: 1715–22.
- Knezevic B, Sprigg D, Seet J, Trevenen M, Trubiano J, Smith W *et al.* The revolving door: antibiotic allergy labelling in a tertiary care centre. *Intern Med J* 2016; **46**: 1276–83.
- Lucas M, Arnold A, Sommerfield A, Trevenen M, Braconnier L, Schilling A *et al.* Antibiotic allergy labels in children are associated with adverse clinical outcomes. *J Allergy Clin Immunol Pract* 2018; **7**: 975–82.
- Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. *Lancet* 2019; **393**: 183–98.
- Arnold A, Coventry LL, Foster MJ, Koplin JJ, Lucas M. The burden of self-reported antibiotic allergies in health care and how to address it: a systematic review of the evidence. *J Allergy Clin Immunol Pract* 2023; **11**: 3133–45.e3.
- Chua KYL, Vogrin S, Bury S, Douglas A, Holmes NE, Tan N *et al.* The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. *Clin Infect Dis* 2020; **73**: 487–96.
- Rose MT, Slavin M, Trubiano J. The democratization of de-labeling: a review of direct oral challenge in adults with low-risk penicillin allergy. *Expert Rev Anti Infect Ther* 2020; **18**: 1143–53.
- Copaescu AM, Li L, Blumenthal KG, Trubiano JA. How to define and manage low-risk drug allergy labels. *J Allergy Clin Immunol Pract* 2024; **12**: 1095–106.
- Trubiano J, Phillips E. Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'. *Curr Opin Infect Dis* 2013; **26**: 526–37.
- Australian Commission on Safety and Quality in Health Care. *Antimicrobial Stewardship in Australian Health Care 2018*. Sydney: Australian Commission on Safety and Quality in Health Care; 2018 [cited 2024 Jun 2]. Available from URL: <https://www.safetyandquality.gov.au/sites/default/files/migrated/AMSAH-Book-WEB-COMplete.pdf>.
- World Health Organization. *Antimicrobial Stewardship Interventions: A Practice Guide*. Geneva: WHO; 2021 [cited 2024 Jun 2]. Available from URL: <https://www.euro.who.int/en/publications/abstracts/antimicrobial-stewardship-interventions-a-practical-guide-2021>.
- World Health Organization (Europe). *Antimicrobial Stewardship Interventions: A Practical Guide*. Geneva: WHO; 2021.
- Australian Commission on Safety and Quality in Health Care. *Antimicrobial Stewardship Clinical Care Standard*. Sydney: Australian Commission on Safety and Quality in Health Care; 2020 [cited 2024 Jun 2]. Available from URL: <https://www.safetyandquality.gov.au/our-work/clinical-care-standards/antimicrobial-stewardship-clinical-care-standard>.
- Brusco NK, Bury S, Chua K, Vogrin S, Holmes NE, Trubiano J. Penicillin allergy delabeling program: an exploratory economic evaluation in the Australian context. *Intern Med J* 2021; **53**: 74–83.
- Li J, Shahabi-Sirjani A, Figtree M, Hoyle P, Fernando SL. Safety of direct drug provocation testing in adults with penicillin allergy and association with health and economic benefits. *Ann Allergy Asthma Immunol* 2019; **123**: 468–75.
- Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. *Lancet* 2017; **390**: 1996–2011.
- Devchand M, Trubiano JA. Penicillin allergy: a practical approach to assessment and prescribing. *Aust Prescr* 2019; **42**: 192–9.
- Turner PJ, Worm M, Ansotegui IJ, El-Gamal Y, Rivas MF, Fineman S *et al.* Time to revisit the definition and clinical criteria for anaphylaxis? *World Allergy Organ J* 2019; **12**: 100066.
- Wrenn RH, Trubiano JA. Penicillin allergy impact and management. *Infect Dis Clin North Am* 2023; **37**: 793–822.
- Powell N, Upton M, Kent B, Sandoe J, Tonkin-Crine S. Non-allergist healthcare workers views on delivering a penicillin allergy de-labelling inpatient pathway: identifying the barriers and enablers. *JAC Antimicrob Resist* 2024; **6**: dlac014.
- Alagoz E, Saucke M, Balasubramanian P, Lata P, Liebenstein T, Kakumanu S. Barriers to penicillin allergy de-labeling in the inpatient and outpatient settings: a qualitative study. *Allergy Asthma Clin Immunol* 2023; **19**: 88.
- Wilson A, Trubiano JA, Chua KYL. Patient perspectives on antibiotic allergy delabeling – enablers and barriers. *J Allergy Clin Immunol Pract* 2020; **8**: 3637–9.e5.
- Loprete J, Katelaris CH, Evans L, Kane A, McMullan B, Wainstein B *et al.* Standardized testing and written communication improve patient understanding of beta-lactam allergy testing outcomes: a multicenter, prospective study. *J Allergy Clin Immunol Glob* 2022; **1**: 99–105.
- Powell N, Upton M, Kent B, Sandoe J, Tonkin-Crine S. Experiences of an inpatient penicillin allergy de-labelling pathway: capturing the patient voice. *JAC Antimicrob Resist* 2024; **6**: dlac020.
- Mitri E, Reynolds G, Hornung CJ, Trubiano JA. Low-risk penicillin allergy delabeling: a scoping review of direct oral challenge practice, implementation,

- and multi-disciplinary approaches. *Expert Rev Anti Infect Ther* 2024; **22**: 59–69.
- 26 Powell N, Stephens J, Kohl D, Owens R, Ahmed S, Musicha C *et al.* The effectiveness of interventions that support penicillin allergy assessment and delabeling of adult and pediatric patients by nonallergy specialists: a systematic review and meta-analysis. *Int J Infect Dis* 2023; **129**: 152–61.
 - 27 Devchand M, Urbancic KF, Khumra S, Douglas AP, Smibert O, Cohen E *et al.* Pathways to improved antibiotic allergy and antimicrobial stewardship practice: the validation of a beta-lactam antibiotic allergy assessment tool. *J Allergy Clin Immunol Pract* 2019; **7**: 1063–5.e5.
 - 28 Trubiano J, Vogrin S, Holmes NE, Chua K, Douglas A, Bourke J *et al.* Development and validation of a penicillin allergy clinical decision rule. *JAMA Intern Med* 2020; **180**: 745–52.
 - 29 Safer Care Victoria. *Check Again Report*. Melbourne: Safer Care Victoria; 2024 [cited 2024 Jun 2]. Available from URL: https://www.safercare.vic.gov.au/sites/default/files/2024-09/check_again_collaborative_-_executive_summary_of_the_evaluationv2.pdf
 - 30 Safer Care Victoria. Antibiotic allergy de-labelling program; 2020 [cited 2024 Jun 2]. Available from URL: <https://www.safercare.vic.gov.au/improvement/projects/mtip/antibiotic-allergy-delabelling>
 - 31 du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. *J Antimicrob Chemother* 2019; **74**: 1438–46.
 - 32 Steenvoorden L, Bjoernestad EO, Kvesetmoen TA, Gulsvik AK. De-labelling penicillin allergy in acutely hospitalized patients: a pilot study. *BMC Infect Dis* 2021; **21**: 1083.
 - 33 Devchand M, Kirkpatrick C, Stevenson W, Garrett K, Perera D, Khumra S *et al.* Evaluation of a pharmacist-led penicillin allergy de-labelling ward-round – a novel antimicrobial stewardship intervention. *J Antimicrob Chemother* 2019; **74**: 1725–30.
 - 34 Mitri E, Vogrin S, Copaescu AM, Waldron J, Cox F, Devchand M *et al.* The long-term impact of a pharmacist-led antimicrobial stewardship penicillin allergy delabeling ward round. *J Allergy Clin Immunol* 2024; **153**: AB153.
 - 35 Ramsey A, Mustafa SS, Holly AM, Staicu ML. Direct challenges to penicillin-based antibiotics in the inpatient setting. *J Allergy Clin Immunol Pract* 2020; **8**: 2294–301.
 - 36 Trubiano JA, Vogrin S, Mitri E, Hall R, Copaescu A, Waldron J *et al.* The who, what, when and where of inpatient direct oral penicillin challenge – implications for health services implementation. *Clin Infect Dis* 2023; **77**: 19–22.
 - 37 Patel VM, Chu B, Hamilton KW, Bellamy C, Harker C, Bryer JS *et al.* Penicillin allergy evaluation in hospitalized patients with hematologic malignancy. *Antimicrob Steward Healthc Epidemiol* 2023; **3**: e92.
 - 38 Merz LE, Huang GX, Mehta GD, Lynch DM, Maliborski N, Besz K *et al.* Development of a pipeline for removing allergy labels in patients undergoing hematopoietic stem cell transplantation. *Transplant Cell Ther* 2024; **30**: 322.e1–e10.
 - 39 Rose M, Mitri E, Vogrin S, Holmes N, Chua K, Lambros B *et al.* Durability of penicillin allergy delabelling in patients with immune compromise. *J Allergy Clin Immunol* 2024; **153**: AB164.
 - 40 Waldron JL, Trubiano JA. Antibiotic allergy labels in immunocompromised populations. *Transpl Infect Dis* 2022; **24**: e13955.
 - 41 Gorsline CA, Afghan AK, Stone CA Jr, Phillips EJ, Satyanarayana G. Safety and value of pretransplant antibiotic allergy delabeling in a quaternary transplant center. *Transpl Infect Dis* 2022; **24**: e13885.
 - 42 Trubiano JA, Vogrin S, Copaescu A, Nasra M, Douglas A, Holmes NE *et al.* Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: a multicenter cohort study. *Allergy* 2022; **77**: 1038–42.
 - 43 Antibiotic Expert Groups. *Therapeutic Guidelines: Antibiotic. Version 16*. Melbourne: Therapeutic Guidelines Limited; 2019.
 - 44 Powell N, Elkhaila S, Sandoe J. Penicillin allergy de-labelling by non-allergists: a comparison of testing protocols. *JAC Antimicrob Resist* 2023; **5**: dlad134.
 - 45 Copaescu AM, Vogrin S, James F, Chua KYL, Rose MT, De Luca J *et al.* Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: the PALACE randomized clinical trial. *JAMA Intern Med* 2023; **183**: 944–52.
 - 46 Piotin A, Godet J, Trubiano JA, Grandbastien M, Guenard-Bilbault L, de Blay F *et al.* Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. *Ann Allergy Asthma Immunol* 2022; **128**: 27–32.
 - 47 Castagna J, Chasset F, Autegarden JE, Le Thai C, Amsler E, Barbaud A *et al.* Assessing delayed penicillin hypersensitivity using the PENFAST+ score. *Front Allergy* 2023; **4**: 1302567.
 - 48 Rose MT, Holmes NE, Eastwood GM, Vogrin S, James F, De Luca JF *et al.* Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial. *Intensive Care Med* 2024; **50**: 913–21.
 - 49 Copaescu AM, Vogrin S, Shand G, Ben-Shoshan M, Trubiano JA. Validation of the PEN-FAST score in a pediatric population. *JAMA Netw Open* 2022; **5**: e2233703.
 - 50 Australasian Society of Clinical Immunology and Allergy. ASCIA consensus statement for the assessment of patients with suspected penicillin allergy 2020 [cited 2024 Jun 2]. Available from URL: https://www.allergy.org.au/images/stories/hp/info/ASCIA_HP_Consensus_Penicillin_Allergy_2020.pdf
 - 51 Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA *et al.* Drug allergy: a 2022 practice parameter update. *J Allergy Clin Immunol* 2022; **150**: 1333–93.
 - 52 Kulalert P, Phinyo P, Chiriac AM, Demoly P, Saokaew S, Kanchanaphoomi K *et al.* Is a prolonged drug provocation test better than a single-day drug provocation test? A systematic review and meta-analysis. *J Allergy Clin Immunol Pract* 2024; **12**: 431–48.
 - 53 Leis JA, Palmay L, Ho G, Raybardhan S, Gill S, Kan T *et al.* Point-of-care beta-lactam allergy skin testing by antimicrobial stewardship programs: a pragmatic multicenter prospective evaluation. *Clin Infect Dis* 2017; **65**: 1059–65.
 - 54 Heil EL, Bork JT, Schmalzle SA, Kleinberg M, Kewalramani A, Gilliam BL *et al.* Implementation of an infectious disease fellow-managed penicillin allergy skin testing service. *Open Forum Infect Dis* 2016; **3**: ofw155.

- 55 Fernandez J, Torres MJ, Campos J, Arribas-Poves F, Blanca M, DAP-Diater Group. Prospective, multicenter clinical trial to validate new products for skin tests in the diagnosis of allergy to penicillin. *J Invest Allergol Clin Immunol* 2013; **23**: 398–408.
- 56 Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB *et al.* Skin test concentrations for systemically administered drugs – anENDA/EAACIDrug Allergy Interest Group position paper. *Allergy* 2013; **68**: 702–12.
- 57 Ali S, Le T-T, Yuson C, Kette F, Smith W, Hissaria P. Major and minor penicillin determinants in penicillin allergy testing: a South Australian experience. *World Allergy Organ J* 2020; **13**: 100248.
- 58 Legendre DP, Muzny CA, Marshall GD, Swiatlo E. Antibiotic hypersensitivity reactions and approaches to desensitization. *Clin Infect Dis* 2014; **58**: 1140–8.
- 59 Picard M, Robitaille G, Karam F, Daigle J-M, Bédard F, Biron É *et al.* Cross-reactivity to cephalosporins and carbapenems in penicillin-allergic patients: two systematic reviews and meta-analyses. *J Allergy Clin Immunol Pract* 2019; **7**: 2722–38.e5.
- 60 Trubiano JA, Stone CA, Grayson ML, Urbancic K, Slavin MA, Thursky KA *et al.* The 3 Cs of antibiotic allergy-classification, cross-reactivity, and collaboration. *J Allergy Clin Immunol Pract* 2017; **5**: 1532–42.
- 61 Khan DA, Phillips EJ, Accarino JJ, Gonzalez-Estrada A, Otani IM, Ramsey A *et al.* United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions. *J Allergy Clin Immunol* 2023; **152**: 1581–6.
- 62 Watts TJ. Grading immediate drug reactions: adopting a robust diagnostic approach. *J Allergy Clin Immunol* 2024; **153**: 1162.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher's web-site:

Appendix S1 Supporting Information.
